Escape velocity out of a small base: management describes the business compounding at a rate its own size cannot absorb
The model's full reasoning — Q1 2018 call → NOWe need to answer YES or NO based on the criteria. The question asks: does management describe the company as being at a point where the RATE at which its business is accumulating has become the dominant fact about it — that is, does management convey, in its own words, that the company keeps having to describe itself in terms of MULTIPLES OR REPEATED DOUBLINGS of its own recent past rather than in terms of incremental progress, and that this compounding is happening off a base management treats as still small? We need to check the transcript for management's own words. Look for phrases like "doubled", "tripled", "several times", "up from almost nothing", "more in this period than in all prior periods combined", etc. Also check if management treats the company as still small relative to what is happening. Let's scan the transcript. Jeff Albers speaks about progress. He mentions "we have three home grown and wholly owned clinical candidates with compelling proof of concept, rapidly expanding research portfolio and line of sight to delivering our first approved medicine to patients." That's not a multiple. He mentions "we recently nominated another wholly owned research program that we hope to advance in a similar manner." Not a multiple. He talks about BLU-667 data. "we were thrilled to share initial results for BLU-667 in patients with RET-altered cancers at AACR." He says "we think it’s worth stressing how our progress to-date with BLU-667 is truly representative of our vision and scientifically driven approach." No multiples. He mentions "high preliminary response rates" etc. No multiples. Andy Boral talks about BLU-667. He says "84% of patients with measurable disease and tumor reductions" etc. No multiples. He mentions "we’ve seen more confirmed and initial responses the passage of time." No multiples. He talks about avapritinib. "we completed enrollment of the PDGFR-alpha and third line just plus expansion cohorts in the Phase 1 NAVIGATOR trial. In total, we’ve enrolled more than 50 patients with PDGFR-alpha driven GIST and more than 100 patients with third line plus KIT-driven GIST." That's numbers but not multiples. He mentions "we recently activated the first clinical site for our Phase 3 VOYAGER trial" etc. He talks about PATHFINDER trial. "The PATHFINDER trial will enroll approximately 60 patients" etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
SNOW · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Frank Slootman repeatedly frames the current state in terms of multiples of the recent past: product revenue “growing 110% year-on-year” (more than doubling), EMEA “up 174%” and Asia-Pacific “219%”, BUILD Summit registrations “three times last year’s”, Snow Day “ 23,000 registrations”, Data Marketplace “grew 41%”, stable edges “more than 130% annual increase”, Powered By Snowflake partners “growing 137% quarter-on-quarter” and product revenue from them “173% year-on-year”.
DASH · Q3 2023 → YESThe question is whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as still sm...YES The transcript shows management repeatedly framing the business in terms of multiples of its recent past: non-restaurant selection "going from 0 nearly 3 years ago to a multibillion-dollar business that's at scale now growing fast"; grocery GOV "has doubled year-on-year"; international growth "at multiples of what we see around the world"; and new verticals accelerating from the prior quarter.
SYM · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Management repeatedly frames the current state using multiples of recent past activity: backlog more than doubled (from $5.2B to $11.